Original Research and the Latest News

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

by | October 26, 2025 | Business, Data Analytics, Industry Trends, Market Scan, New Technology, Probability of Success | 0 Comments

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | October 16, 2025 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

We’re Back!

Oct 27, 2017 |

Ozmosi has been on a purpose-driven hiatus peppered with innovation, development and growth. In less than one year, we have...

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
22 Dec

$NBIX +1.67% today as Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

More Info: https://pryzm.ozmosi.com/product/2327

Reply on Twitter 2003214234797355252 Retweet on Twitter 2003214234797355252 Like on Twitter 2003214234797355252 Twitter 2003214234797355252
ozmosihealth Ozmosi @ozmosihealth ·
22 Dec

$ENTX +5.40% today as Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

More Info: https://pryzm.ozmosi.com/product/25811

Reply on Twitter 2003214231693668689 Retweet on Twitter 2003214231693668689 Like on Twitter 2003214231693668689 1 Twitter 2003214231693668689
ozmosihealth Ozmosi @ozmosihealth ·
22 Dec

$AB -0.68% today as AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

More Info: https://pryzm.ozmosi.com/product/1289

Reply on Twitter 2003214229072150679 Retweet on Twitter 2003214229072150679 Like on Twitter 2003214229072150679 Twitter 2003214229072150679
ozmosihealth Ozmosi @ozmosihealth ·
22 Dec

$ENTX +5.40% today as Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

More Info: https://pryzm.ozmosi.com/product/25811

Reply on Twitter 2003125253485011014 Retweet on Twitter 2003125253485011014 Like on Twitter 2003125253485011014 1 Twitter 2003125253485011014
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762